Pulmotech MAA Market Report 2026

Pulmotech MAA Market Overview

• The Pulmotech MAA market growth in the historic period has been driven by increasing prevalence of pulmonary embolism cases, expansion of nuclear medicine departments in hospitals • Market expansion is supported by increasing demand for early and accurate pulmonary diagnostics, rising investments in nuclear medicine infrastructure • Growth Driver: Impact Of Rising Respiratory Disease Prevalence On The Growth Of The Market • North America was the largest region in 2025.

What Is Covered Under Pulmotech MAA Market?

Pulmotech MAA is a radiopharmaceutical agent used in lung scintigraphy to evaluate pulmonary perfusion. It consists of technetium Tc 99m-labeled aggregated human serum albumin particles, which, when injected intravenously, become temporarily lodged in the lung capillaries, allowing for imaging of blood flow in the lungs The main applications of pulmotech MAA are pulmonary embolism diagnosis, preoperative assessment, lung transplant viability, chronic respiratory disease evaluation, and clinical research. Pulmonary embolism (PE) is a blockage in one of the pulmonary arteries in the lungs, typically caused by blood clots. The distribution channels are direct sales, distributors, and online platforms, and it is used by various end users such as hospitals, research institutions, and diagnostic imaging centers.

What Is The Pulmotech MAA Market Growth Forecast?

The growth in the forecast period can be attributed to increasing demand for early and accurate pulmonary diagnostics, rising investments in nuclear medicine infrastructure, expansion of clinical research using radiotracers, growing focus on personalized diagnostic imaging, technological advancements in imaging agents. Major trends in the forecast period include increasing adoption of advanced lung perfusion imaging agents, rising use of nuclear medicine in pulmonary diagnostics, growing demand for accurate pulmonary embolism detection, expansion of radiopharmaceutical clinical applications, enhanced focus on imaging accuracy and safety.

What Are The Drivers Of The Pulmotech MAA Market?

The increasing prevalence of respiratory diseases is expected to propel the growth of the pulmotech MAA market going forward. Respiratory diseases refer to a broad range of conditions that affect the lungs and other parts of the respiratory system, which include the airways, lungs, and respiratory muscles. A combination of environmental pollutants, lifestyle factors, aging populations, and advancements in diagnostic methods drives the increasing prevalence of respiratory diseases. Pulmotech MAA is used to diagnose and manage chronic respiratory conditions by aiding in pulmonary imaging to assess regional lung function and detect potential abnormalities such as perfusion deficits. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based health and welfare agency, approximately 8.5 million people in Australia, or 34% of the population, were estimated to have chronic respiratory conditions. This includes an estimated 2.8 million people, or 11% of the population, living with asthma and 638,000 people, or 2.5% of the population, living with chronic obstructive pulmonary disease (COPD). Therefore, the increasing prevalence of respiratory diseases is driving the pulmotech MAA industry. The growing prevalence of chronic diseases to propel the growth of the pulmotech MAA market going forward. Chronic diseases refer to medical conditions that persist over an extended period, often lasting for years or a lifetime. The growing prevalence of chronic diseases is primarily driven by lifestyle changes, aging populations, and environmental factors. Pulmotech MAA can be valuable for managing the ever-increasing prevalence of chronic diseases, particularly those affecting the respiratory system. Pulmotech MAA is utilized in evaluating and managing chronic diseases by enabling precise imaging of pulmonary perfusion, aiding in diagnosing conditions such as pulmonary embolism, and monitoring lung disorders. For instance, in April 2025, according to the National Center for Health Statistics (NCHS) under the Centers for Disease Control and Prevention (CDC), a US-based publication of health statistics data indicated a trend of rising chronic diseases, particularly among young and midlife adults. Among young adults, obesity prevalence increased from 27.3% in 2023, and depression rose from 25.0%, along with increases in diabetes and chronic kidney disease in midlife adults. Therefore, the growing prevalence of chronic diseases is expected to drive the growth of the pulmotech MAA industry. The expanding aging population is expected to propel the growth of the pulmotech MAA market going forward. An aging population is a demographic shift where the proportion of older individuals (typically 65 years and older) increases. The expanding aging population is driven by increased life expectancy due to advances in healthcare, improved living conditions, and better management of chronic diseases. Pulmotech MAA supports the aging population by enabling detailed pulmonary imaging to diagnose and monitor age-related respiratory conditions, aiding in timely and accurate treatment interventions. For instance, in January 2024, according to the statistics published by the Population Reference Bureau (PRB), a US-based nonprofit organization, it is anticipated that the number of Americans 65 and older will climb from 58 million in 2022 to 82 million in 2050 (a 47% increase) and that their proportion of the overall population will increase from 17% to 23%. Therefore, the expanding aging population is driving the pulmotech MAA industry.

Key Players In The Global Pulmotech MAA Market

Major companies operating in the pulmotech maa market are Curium Pharma

What Defines the Pulmotech MAA Market?

The pulmotech MAA market consists of sales of radiopharmaceutical Kits, ready-to-use radiopharmaceuticals, imaging system integration, and emerging product variants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Pulmotech MAA Market Report 2026?

The pulmotech maa market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pulmotech maa industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.